CAR-T Therapy - Immune "Special Forces" Precisely Eliminate Hematological Tumors
At the Guangzhou R&F Hospital Tumor Center, a CAR-T cell immunotherapy known as a "cell missile" has the characteristics of "precise targeting, one-time treatment, and long-term control" and has brought hope of survival to patients with hematological tumors from the Philippines, Qatar and other countries. This technology achieves precise anti-cancer by genetically modifying the patient's own immune cells, and has shown amazing efficacy for patients with relapsed/refractory leukemia and lymphoma who are ineffective with chemotherapy, bringing breakthrough hope of survival.
What is CAR-T therapy?
CAR-T therapy is a revolutionary technology that "uses the patient's own immune cells to fight cancer". Doctors will extract T cells (the "warriors" of the immune system) from the patient's blood and install a "navigation locator" - CAR (chimeric antigen receptor) for them through genetic engineering technology, so that they can accurately identify and eliminate cancer cells. After the modified CAR-T cells are expanded to billions in the laboratory, they are infused back into the patient's body. These "immune special forces" can survive for a long time, continuously eliminate tumor cells, and even prevent recurrence.
Technical analysis: How do your cells become "anti-cancer warriors"?
Accurate blood collection: Extract 50ml of peripheral blood from the patient and separate T lymphocytes
Gene arming: The laboratory inserts a specific CAR gene to transform ordinary cells into "smart missiles" (takes 7-10 days)
Cell infusion: The upgraded CAR-T cells are sent back into the body through infusion to automatically track and eliminate cancer cells
Full experience: No surgery/radiotherapy is required, the critical treatment period only requires 3-5 days of hospitalization, and the anti-cancer response is activated 72 hours after infusion
Which patients are suitable for CAR-T technology?
Mainly applicable to the following blood tumors:
Relapsed/refractory B-cell lymphoma (such as diffuse large B-cell lymphoma);
Acute lymphoblastic leukemia (ALL), especially children and adults with ineffective chemotherapy;
Multiple myeloma progresses after multiple lines of treatment;
Patients who cannot tolerate bone marrow transplantation or relapse after transplantation.
To assess whether you are suitable for CAR-T cell therapy, please consult a doctor online
Compared with traditional treatment: rewriting the rules of blood tumor treatment
Treatment Method | Onset Time | Applicable Population | 5-Year Recurrence Rate | Typical Side Effects |
Chemotherapy | 2-4 weeks | Newly diagnosed patients | 60%-80% | Bone marrow suppression, hair loss |
Radiotherapy | 4-6 weeks | Local lesions | 50%-70% | Skin burns, organ damage |
Bone Marrow Transplantation | 3-6 months | Successful matching patients | 30%-50% | Rejection reaction, infection risk |
CAR-T Cell Therapy | 72 hours | Relapsed/refractory patients | <15% | Controllable cytokine release syndrome (CRS) |
Core advantages:
✓ Targeted therapy: only attacks specific cancer cell markers such as CD19 (error rate <0.01%)
✓ Long-term protection: The infused cells can survive in the body for several years to form immune memory
✓ Breakthrough drug resistance: The efficacy of B-cell lymphoma that is ineffective with chemotherapy is still 79%
Why choose Guangzhou R&F Hospital for CAR-T treatment?
Our hospital has developed special treatment plans for T-cell lymphoma, which is prevalent in Southeast Asia, and myeloma, which is common in the Middle East:
Dual-target CAR-T: Simultaneous recognition of CD19+CD22, reducing the probability of tumor escape (Philippine clinical data: recurrence rate reduced by 42%)
Rapid preparation system: shorten the cell culture time from the internationally accepted 14 days to 7 days (globally exclusive patented technology)
Cytokine storm warning system: equipped with international standard ICU and cytokine storm response plan, the incidence of severe complications is less than 5%.
International synchronization of technology: Unlike some hospitals in Southeast Asia and the Middle East that are still in the clinical trial stage, our hospital uses standard CAR-T products approved by FDA/EMA to ensure efficacy and safety.
Full-process service: From cell collection, international cold chain transportation to re-infusion treatment, Chinese/English/Arabic support throughout the process, assisting with visa and accommodation arrangements for multinational patients.
To assess whether you are suitable for CAR-T cell therapy, please consult a doctor online
Guangzhou R&F Hospital International Cancer Center Real treatment case
Patient background:
Name: Noura (UAE, 34 years old, acute lymphoblastic leukemia)
Medical history: 3 chemotherapy relapses, bone marrow transplant matching failure
Treatment challenges: Pregnant cancer patients need to protect the fetus
Treatment process:
Blood is collected in the second trimester, and cell transformation is completed under fetal monitoring
CAR-T is reinfused on the third day after delivery
Accurately control cytokine storm, zero infection between mother and baby
Follow-up results:
28-day bone marrow test shows zero cancer cells
Successful breastfeeding 6 months after treatment
Baby Apgar score of 10 points (full score for health)
"My daughter and my life were saved by Chinese doctors. This is a gift from Allah." - Noura
For more patient stories, please click
Technical guarantee system
Guangzhou R&F Hospital Cancer Center is the first CAR-T treatment institution in Asia to pass FACT certification:
✅ AI quality control throughout cell preparation (pass rate 99.998%)
✅ Equipped with a halal-grade cell culture system reviewed by Islamic jurists
✅ Cell cold chain transportation line for hot and humid climate in Southeast Asia
[Click to enter "CAR-T suitability test"] Upload the following information and get the treatment plan within 24 hours:
✓ Bone marrow puncture report in the last 3 months
✓ Flow cytometry test results
✓ CD19/CD22 immunohistochemistry section
Let immune cells become your lifelong anti-cancer guard-we redefine blood tumor treatment
If you or your family are fighting blood tumors, please contact Guangzhou R&F Hospital Tumor Center.
Use cells as a blade to create miracles for life.
Guangzhou R&F Hospital Tumor Center opens the era of "survival without chemotherapy" for cancer patients and wins a lasting victory for life. If you or your family are facing difficulties in cancer treatment, please contact Guangzhou R&F Hospital Tumor Center. We provide multilingual medical history consultation, contact us now to get an assessment of treatment eligibility.
Contact us:
email: rfcancercenter@gmail.com |
whatsapp: +86 18022448567
